Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the challenges that come with trying to develop a clinical trial for biosimilars.
Michael A. Savin, MD
Advertisement
Articles by Michael A. Savin, MD
Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the evolution of biosimilars.
Michael A. Savin, MD, assistant professor of medicine, School of Medicine, Oregon Health and Science University, discusses the future of biosimilars in oncology.
Advertisement
Latest Updated Articles
Dr. Savin on the Evolution of BiosimilarsJune 16th 2018
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5